Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.
A grade PMID 42321916
View analysis →A grade PMID 42690647
View analysis →A grade PMID 42372741
View analysis →A grade PMID 42216567
View analysis →A grade PMID 41916649
View analysis →A grade PMID 42382416
View analysis →A grade PMID 42150584
View analysis →B grade PMID 42748428
View analysis →A grade PMID 41756844
View analysis →A grade PMID 42765973
View analysis →A grade PMID 42362103
View analysis →A grade PMID 42101908
View analysis →This Review provides a practical framework for evaluating methylation profile scores in children and adolescents, including their emerging use in paediatric brain-tumour diagnostics, treatment-response prediction, and longitudinal treatment monitoring, while emphasizing that most remain early-stage research tools.
The record supports MPSs as developing biomarkers with potential diagnostic and treatment-monitoring applications; it is reasonable but still inferential to hypothesize that validated paediatric MPSs could eventually improve therapy selection or response assessment in childhood cancers, because no oncology intervention study or clinical outcome is reported.
This two-patient pediatric case series reports laryngotracheal mucosal neuromas causing obstruction and progressive respiratory compromise as the initial presentation of RET mutation-confirmed MEN2B.
The reported cases support airway evaluation and prompt RET testing when children with obstruction also have MEN2B-associated phenotypic or familial features; it is an inference, not tested here, that earlier recognition and multidisciplinary management could accelerate MEN2B-directed surveillance and treatment and reduce airway morbidity.
In a cross-sectional questionnaire study, 54 children with leukemia or lymphoma had moderately greater parent-reported sleep disturbance than matched children with benign hematologic conditions, particularly sleep anxiety and parasomnias, with recent hospitalization strongly associated with sleep burden.
The evidence identifies hospitalization-associated sleep disturbance as a potential supportive-care target; it is reasonable to hypothesize that screening and hospital-based sleep interventions could reduce sleep burden, but this study did not test an intervention, establish causality, or demonstrate improved clinical outcomes.
This systematic review of 44 studies and 3,043 patients with non-mucosal cutaneous squamous cell carcinoma found that sentinel lymph node biopsy had high node-detection and low complication rates, while positivity was associated with aggressive tumor features, recurrence, and disease-specific mortality, but false negatives remained notable.
The evidence supports SLNB as a possible staging and prognostic tool in selected high-risk cSCC rather than as a treatment; it can only be inferred—not established from this review—that improved risk stratification might guide surveillance or treatment selection, and pediatric applicability is unsupported because pediatric cases were explicitly excluded.
In a SEER-based cohort of 3,378 adults with prolactinoma, all-cause mortality was modestly elevated overall and concentrated in an older, male-predominant profile characterized by larger tumors.
The evidence supports clinically heterogeneous mortality risk associated with age, sex, and tumor size; it may justify testing whether profile-directed surveillance or treatment optimization improves outcomes, but no therapeutic intervention, causal mechanism, or treatment benefit was evaluated.
This nationwide Taiwanese registry cohort reports that females diagnosed with cancer at age 39 years or younger had about half the expected number of births, with childbirth rates varying by cancer type, age at diagnosis, and chemotherapy exposure.
The evidence supports identifying survivor groups with reduced post-cancer childbirth and prioritizing early fertility counseling; it is an inference, not tested here, that expanded fertility-preservation and oncofertility services would improve subsequent reproductive outcomes.
Using Global Burden of Disease data from 1990–2021, this cross-sectional study combines cancer burden and a principal-component-derived quality-of-care index to classify 34 cancers across 204 countries and reports marked socioeconomic, age, and gender disparities, including stagnant quality improvement among adolescents.
The study provides no evidence for a specific anticancer therapy; it supports the inference that burden–quality stratification could help direct resources, reduce possible overtreatment, and identify underserved populations, but prospective evidence that this framework improves pediatric cancer care or outcomes is required.
This secondary GBD 2021 analysis estimates that tracheal, bronchus, and lung cancer caused 28,004 incident cases, 22,622 deaths, and 1,291,020 DALYs among people aged 15–39 years in 2021, with burden and trends varying by age, sex, and socioeconomic development.
Evidence: the analysis identifies demographic and geographic disparities in AYA lung-cancer burden, including rising burden in low-SDI regions and increased cases and prevalence among females. Inference: these patterns could help target tobacco/nicotine control, exposure reduction, diagnostic access, and future treatment-resource studies, but the record does not test any preventive or therapeutic intervention or establish which exposures caused the observed trends.
In a human observational cohort of 47 patients with breast cancer liver metastases, the study reports enrichment for young-onset and recent-postpartum disease, frequent ER-positive replacement-pattern metastases, and histologic findings consistent with use of existing liver sinusoids.
The evidence supports associations among young or postpartum status, luminal breast cancer, and liver metastasis characteristics; it only suggests—not demonstrates—that postpartum liver biology or sinusoid-dependent replacement growth could eventually inform risk stratification or provide therapeutic targets.
This narrative review applies the WHO pediatric palliative-care integration framework to childhood cancer care in Cuba and identifies gaps in specialist training, home opioid access, formal palliative-care teams, and outcomes research across eight oncology reference centers.
The review supports the inference—not a tested clinical conclusion—that aligning Cuba's pediatric oncology services with the WHO model, including stronger training, multidisciplinary teams, and improved home opioid access, could improve continuity, symptom management, and quality of life; no patient-level intervention or outcome effect is demonstrated.
In a Canadian population-based cohort of more than 965,000 children, higher estimated prenatal outdoor ultrafine-particle exposure was associated with imprecise increases in ALL and neuroblastoma incidence, while confidence intervals included the null and results differed across cancer groups.
The observational evidence suggests a possible prenatal environmental risk signal for ALL and neuroblastoma; if future studies establish causality, reducing gestational ultrafine-particle exposure could become a population-level cancer-prevention strategy, but this record does not test an intervention or support a clinical recommendation.
In a prospective cohort of 145 adult childhood cancer survivors attending their first long-term follow-up visit at two Swiss clinics, satisfaction was high, discussion of more desired topics was associated with greater patient-centered-care satisfaction, and lower mental health-related quality of life was associated with greater worries.
The study provides observational evidence that addressing survivors’ desired discussion topics correlates with satisfaction and that lower mental HRQoL correlates with worry; it supports, but does not test, the hypothesis that agenda-based consultations and targeted psychological support could improve the follow-up experience and reduce worries.
